The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posed a serious public health concern and started a race against time for researchers to discover an effective and safe therapy for coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2. This review aims to describe the history, efficacy, and safety of five potential therapeutics for COVID-19, remdesivir, favipiravir, hydroxychloroquine, tocilizumab, and convalescent plasma. A literature review was conducted through October 2020 to identify published studies evaluating the efficacy and safety of these five potential therapeutics. Clinical improvement was used to assess the efficacy, while reported withdrawals from study participation and adverse events were used to evaluate the safety. In total, 95 clinical studies (6 interventional and 89 observational studies) were obtained, of which 42 were included in this review. The evaluation of the efficacy and safety profiles is challenging due to the limitations of the clinical studies on one hand, and the limited number of randomized controlled trials (RCTs) on the other. Moreover, there was insufficient evidence to support repurposing remdesivir, favipiravir, and tocilizumab for COVID-19.

中文翻译：

---

潜在治疗方法的历史、功效和安全性：COVID-19 复杂生命的叙述性概述


严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 大流行引发了严重的公共卫生问题，研究人员开始争分夺秒地寻找针对 2019 冠状病毒病 (COVID-19) 的有效且安全的疗法。 SARS-CoV-2。本综述旨在描述治疗 COVID-19 的五种潜在疗法：瑞德西韦、法匹拉韦、羟氯喹、托珠单抗和恢复期血浆的历史、疗效和安全性。我们于 2020 年 10 月进行了一项文献综述，以确定评估这五种潜在疗法的疗效和安全性的已发表研究。临床改善用于评估疗效，而报告的退出研究参与和不良事件则用于评估安全性。总共获得了 95 项临床研究（6 项介入性研究和 89 项观察性研究），其中 42 项纳入本次评价。一方面由于临床研究的局限性，另一方面由于随机对照试验（RCT）数量有限，对疗效和安全性的评估具有挑战性。此外，没有足够的证据支持将瑞德西韦、法匹拉韦和托珠单抗重新用于治疗 COVID-19。